Worldwide Network for Blood and Marrow Transplantation Recommendations for Establishing a Hematopoietic Stem Cell Transplantation Program in Countries with Limited Resources, Part II: Clinical, Technical, and Socioeconomic Considerations.

[1]  P. Hari,et al.  Comparison of Graft Acquisition and Early Direct Charges of Haploidentical Related Donor Transplantation versus Umbilical Cord Blood Transplantation. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[2]  A. Ravi Ravindran,et al.  Optimizing outpatient appointment system using machine learning algorithms and scheduling rules: A prescriptive analytics framework , 2018, Expert Syst. Appl..

[3]  N. Dayal,et al.  Hematopoietic stem cell transplantation using non-cryopreserved peripheral blood stem cells graft is effective in multiple myeloma and lymphoma , 2018, Bone Marrow Transplantation.

[4]  M. Murad,et al.  Steroid Refractory Chronic Graft-Versus-Host Disease: Cost-Effectiveness Analysis. , 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[5]  P. Rebulla,et al.  Platelet Transfusion for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  L. Shulman,et al.  Cost of Providing Quality Cancer Care at the Butaro Cancer Center of Excellence in Rwanda , 2017, Journal of global oncology.

[7]  R. Gale,et al.  Freezing the graft is not necessary for autotransplants for plasma cell myeloma and lymphomas , 2018, Bone Marrow Transplantation.

[8]  E. Leifer,et al.  Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Jonathan P. Kerr,et al.  Guidelines for the use of platelet transfusions , 2017, British journal of haematology.

[10]  D. Denning,et al.  Global access to antifungal therapy and its variable cost. , 2016, The Journal of antimicrobial chemotherapy.

[11]  Vijetha Vemulapalli,et al.  Non-obvious correlations to disease management unraveled by Bayesian artificial intelligence analyses of CMS data , 2016, Artif. Intell. Medicine.

[12]  Hongmin Cai,et al.  Discrimination of Breast Cancer with Microcalcifications on Mammography by Deep Learning , 2016, Scientific Reports.

[13]  J. Klein,et al.  Comparing Outcomes with Bone Marrow or Peripheral Blood Stem Cells as Graft Source for Matched Sibling Transplants in Severe Aplastic Anemia across Different Economic Regions. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[14]  Gil Alterovitz,et al.  Classification of hospital acquired complications using temporal clinical information from a large electronic health record , 2016, J. Biomed. Informatics.

[15]  Venkatesh Saligrama,et al.  Prediction of hospitalization due to heart diseases by supervised learning methods , 2015, Int. J. Medical Informatics.

[16]  A. Prete,et al.  Biosimilar granulocyte–colony‐stimulating factor for mobilization of autologous peripheral blood stem cells in pediatric hematology‐oncology patients , 2015, Transfusion.

[17]  Sung-Soo Yoon,et al.  Total costs and clinical outcome of hematopoietic stem cell transplantation in adults with leukemia: comparison between reduced‐intensity and myeloablative conditioning , 2015, Clinical transplantation.

[18]  Parham Azimi,et al.  Designing of an intelligent self-adaptive model for supply chain ordering management system , 2015, Eng. Appl. Artif. Intell..

[19]  D. Bates,et al.  Big data in health care: using analytics to identify and manage high-risk and high-cost patients. , 2014, Health affairs.

[20]  S. Ramsey,et al.  Design of a cost-effectiveness analysis alongside a randomized trial of transplantation using umbilical cord blood versus HLA-haploidentical related bone marrow in advanced hematologic cancer. , 2014, Journal of comparative effectiveness research.

[21]  B. Cho,et al.  Comparable long‐term outcomes after reduced‐intensity conditioning versus myeloablative conditioning allogeneic stem cell transplantation for adult high‐risk acute lymphoblastic leukemia in complete remission , 2013, American journal of hematology.

[22]  S. Simoens,et al.  Generic Medicines: Solutions for a Sustainable Drug Market? , 2013, Applied Health Economics and Health Policy.

[23]  M. Jenner,et al.  Use of a biosimilar granulocyte colony‐stimulating factor for peripheral blood stem cell mobilization: an analysis of mobilization and engraftment , 2013, British journal of haematology.

[24]  P. Armand,et al.  Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[25]  E. Wood,et al.  A no-prophylaxis platelet-transfusion strategy for hematologic cancers. , 2013, The New England journal of medicine.

[26]  I. Abraham,et al.  Clinical safety of biosimilar recombinant human granulocyte colony-stimulating factors , 2013, Expert opinion on drug safety.

[27]  Xi Yongzhi,et al.  The Advanced HLA Typing Strategies for Hematopoietic Stem Cell Transplantation , 2013 .

[28]  P. Parham,et al.  16th IHIW : Review of HLA typing by NGS , 2013, International journal of immunogenetics.

[29]  C. Flowers,et al.  Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  A. Ho,et al.  Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study , 2012, The Lancet.

[31]  Stephanie J. Lee,et al.  Economics of hematopoietic cell transplantation. , 2012, Blood.

[32]  M. Postma,et al.  Cost Benefit and Cost Effectiveness of Antifungal Prophylaxis in Immunocompromised Patients Treated for Haematological Malignancies , 2011, PharmacoEconomics.

[33]  M. Zakerinia,et al.  Non‐cryopreserved hematopoietic stem cell transplantation in multiple myeloma, a single center experience , 2012, Clinical transplantation.

[34]  W. Rasheed,et al.  A simplified method for autologous stem cell transplantation in multiple myeloma. , 2012, Hematology/oncology and stem cell therapy.

[35]  P. Gascón.  Presently available biosimilars in hematology-oncology: G-CSF , 2012, Targeted Oncology.

[36]  B. Larsen,et al.  Stemming the brain drain--a WHO global code of practice on international recruitment of health personnel. , 2011, The New England journal of medicine.

[37]  B. Shaw,et al.  Concerns about the use of biosimilar granulocyte colony-stimulating factors for the mobilization of stem cells in normal donors: position of the World Marrow Donor Association , 2011, Haematologica.

[38]  C. Elie,et al.  First experience of autologous peripheral blood stem cell mobilization with biosimilar granulocyte colony- stimulating factor , 2011, Advances in therapy.

[39]  Xianglin L. Du,et al.  The costs and cost-effectiveness of allogeneic peripheral blood stem cell transplantation versus bone marrow transplantation in pediatric patients with acute leukemia. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[40]  A. Ganser,et al.  Association of Human Development Index with rates and outcomes of hematopoietic stem cell transplantation for patients with acute leukemia. , 2010, Blood.

[41]  S. Roger,et al.  Biosimilars: current status and future directions , 2010, Expert opinion on biological therapy.

[42]  Jeffrey McCullough,et al.  Dose of prophylactic platelet transfusions and prevention of hemorrhage. , 2010, The New England journal of medicine.

[43]  J. Wagner,et al.  Costs of pediatric allogeneic hematopoietic‐cell transplantation , 2010, Pediatric blood & cancer.

[44]  Richard M. Johnson.  Guideline on similar biological medicinal products , 2010 .

[45]  G. Ruiz-Argüelles,et al.  A simplified method for stem cell autografting in multiple myeloma: a single institution experience , 2009, Bone Marrow Transplantation.

[46]  D. Weisdorf,et al.  Costs of hematopoietic cell transplantation: comparison of umbilical cord blood and matched related donor transplantation and the impact of posttransplant complications. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[47]  K. Havemann,et al.  Storage of noncryopreserved periphered blood stem cells for transplantation , 1996, Annals of Hematology.

[48]  D. Zahrieh,et al.  Costs of allogeneic hematopoietic cell transplantation with high-dose regimens. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[49]  D. Zahrieh,et al.  Lower costs associated with hematopoietic cell transplantation using reduced intensity vs high-dose regimens for hematological malignancy , 2007, Bone Marrow Transplantation.

[50]  B. Friedman,et al.  Procedures with the Most Rapidly Increasing Hospital Costs, 2000–2004 , 2007 .

[51]  T. Panzarella,et al.  Feasibility and safety of autotransplants with noncryopreserved marrow or peripheral blood stem cells: a systematic review. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[52]  Douglas K. Martin,et al.  Introduction: promoting global health through biotechnology , 2004, Nature Biotechnology.

[53]  R. Storb,et al.  Duration of immunosuppressive treatment for chronic graft-versus-host disease. , 2004, Blood.

[54]  M. Remberger,et al.  Home care during the pancytopenic phase after allogeneic hematopoietic stem cell transplantation is advantageous compared with hospital care. , 2002, Blood.

[55]  N. Heerema,et al.  Racial and ethnic differences in survival of children with acute lymphoblastic leukemia. , 2002, Blood.

[56]  D. Gómez-Almaguer.  The simplification of the SCT procedures in developing countries has resulted in cost-lowering and availability to more patients , 2002, International journal of hematology.

[57]  E. Vellenga,et al.  Autologous peripheral blood stem cell transplantation in patients with relapsed lymphoma results in accelerated haematopoietic reconstitution, improved quality of life and cost reduction compared with bone marrow transplantation: the Hovon 22 study , 2001, British journal of haematology.

[58]  L. Madero,et al.  Comparative cost analysis of autologous peripheral blood progenitor cell and bone marrow transplantation in pediatric patients with malignancies. , 2001, Haematologica.

[59]  J. Shuster,et al.  Racial differences in the survival of childhood B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group Study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  J. Weeks,et al.  Predicting costs of stem-cell transplantation. , 2000, Journal of Clinical Oncology.

[61]  E. Bass,et al.  Outpatient-based bone marrow transplantation for hematologic malignancies: cost saving or cost shifting? , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  M. Bishop,et al.  Valuing clinical strategies early in development: a cost analysis of allogeneic peripheral blood stem cell transplantation , 1999, Bone Marrow Transplantation.

[63]  D. Blaise,et al.  Clinical and economic comparison of lenograstim-primed blood cells (BC) and bone marrow (BM) allogeneic transplantation. , 1998, Bone marrow transplantation.

[64]  S Meiman,et al.  A detailed analysis of charges for hematopoietic stem cell transplantation at a children’s hospital , 1998, Bone Marrow Transplantation.

[65]  K. Sullivan,et al.  Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. , 1997, Blood.

[66]  P. Morel,et al.  Cost comparative study of autologous peripheral blood progenitor cells (PBPC) and bone marrow (ABM) transplantations for non-Hodgkin’s lymphoma patients , 1997, Bone Marrow Transplantation.

[67]  J. Armitage,et al.  Hematopoietic recovery after allogeneic blood stem-cell transplantation compared with bone marrow transplantation in patients with hematologic malignancies. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  K. Matuszewski,et al.  The Clinical Effectiveness and Financial Impact of Utilizing Peripheral Blood Progenitor Cells as Rescue Therapy following Autologous Bone Marrow Transplant , 1996, International Journal of Technology Assessment in Health Care.

[69]  W. Hop,et al.  Small influence of parental educational level on the survival of children with leukaemia in The Netherlands between 1973 and 1979. , 1996, European journal of cancer.

[70]  P. Bierman,et al.  Costs of care and outcomes for high-dose therapy and autologous transplantation for lymphoid malignancies: results from the University of Nebraska 1987 through 1991. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  A. Deisseroth,et al.  Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: Potential advantage of blood over marrow allografts , 1995 .

[72]  Giralt,et al.  Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. , 1995, Blood.

[73]  S. Goodman,et al.  Factors influencing third party payer costs for allogeneic BMT. , 1993, Bone marrow transplantation.

[74]  Welch Hg.  Valuing Clinical Strategies Early in Their Development , 1992 .

[75]  S. Proctor,et al.  Autologous bone marrow transplantation for high-grade lymphoid malignancy using melphalan/irradiation conditioning without marrow purging or cryopreservation. The Northern Regional Bone Marrow Transplant Group. , 1991, Blood.

[76]  W. McWhirter,et al.  Social class as a prognostic variable in acute lymphoblastic leukaemia , 1983, The Medical journal of Australia.